European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

BD Announces Assay for Identification of COVID-19 Patients at Increased Relative Risks of Intubation with Mechanical Ventilation, Mortality at Hospital Admission Now Available in Europe

by Alex Weber
February 4, 2021
A A
Share on LinkedinShare on Twitter

In conjunction with clinical findings and the results of other laboratory testing, BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes may help clinicians determine the risks of Intubation with Mechanical Ventilation and also of mortality in COVID-19 patients, aiding in patient management decisions

EYSINS, Switzerland, (Feb. 3, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark of BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes with expanded clinical application to help clinicians identify COVID-19 patients at increased relative risk of intubation with mechanical ventilation (IMV) and  mortality at hospital admission, in conjunction with clinical findings and the results of other laboratory testing. By providing deeper understanding of immune responses, clinicians can better understand an appropriate course of action for patients while also prioritizing the use of precious hospital resources.

As an industry leader in immunology research and clinical care, BD tools were utilized for research early in the pandemic and early publications showed that the BD Multitest™ 6-Color TBNK Reagent with Trucount™ Tubes was useful in assessing immune status for COVID-19 patients. Further clinical studies have demonstrated clinically validated cut-off levels and further refined the role BD Multitest™ 6-Color TBNK Reagent with Trucount™ Tubes has along with other testing in determining the COVID-19 patients’ risk of IMV and mortality at hospitalization.

As shown in peer-reviewed clinical studies, some patients with COVID-19 may exhibit a decrease of specific lymphocyte T-cell subsets (CD4+ and/ or CD8+ T-cells), and this decrease is associated with increased risk of IMV and mortality. Knowing a patient’s accurate T-cell count, therefore, can be instrumental in informing the right course of action, and the BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes may aid in these types of determinations.

Results from a study conducted by BD have shown that a COVID-19 patient’s risk for IMV and also mortality is five to six times higher for T-cell subsets below cut-off­ levels of: CD4+ <250 cells/µl and/or CD8+ <100 cells/µl compared to those that were above the cut-off.

“The BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes assay’s new claim related to risks of IMV and mortality may help clinicians better determine an appropriate course of action for hospitalized COVID-19 patients, which is a top priority for this population,” said Puneet Sarin, worldwide president of BD Biosciences. “BD Biosciences has a long history of helping clinicians and patients understand immune function, and this new indication may help guide important care decisions while also prioritizing resources.”

The BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes is used in conjunction with the BD FACSLyric™ and BD FACSCanto™ II Clinical Flow Cytometers for COVID-19 clinical applications.

About the BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes

The BD Multitest™ 6-Color TBNK Reagent with optional BD Trucount™ Tubes is a CE marked 6-color direct immunofluorescence reagent for use with a suitably equipped BD flow cytometer to identify and determine the percentages and absolute counts of T, B and natural killer (NK) cells, as well as the CD4 and CD8 subpopulations of T cells in peripheral blood. The BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes can be used with the BD FACS™ Loader and the BD FACS™ Universal Loader.

In Oct. 2020, the following COVID-19 clinical application was added: determining counts of CD3+CD4+ and/or CD3+CD8+ lymphocytes may be useful in the immunological assessment of SARS-CoV-2 infected individuals with COVID-19 disease. Individuals with COVID-19 disease typically exhibit a decrease of CD3+CD4+ and/or CD3+CD8+ lymphocyte counts with increasing disease severity.

New Clinical Application
CD3+CD4+ and/or CD3+CD8+ lymphocytes counts can also be used as an aid in determining the risk of IMV, and the risk of mortality, in confirmed COVID-19 patients, in conjunction with clinical findings and the results of other laboratory testing.

Tags: < Market

Related Industries

Health

Interview with Mr. Sébastien Huron, CEO, Virbac group

March 6, 2023
Health

Bayer driving innovation in radiology with new research across the portfolio presented at ECR

February 23, 2023
Health

Philips recognized as top innovator for 10th consecutive year

February 17, 2023
Health

Bayer completes acquisition of Blackford Analysis Ltd.

February 14, 2023
Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

January 25, 2023
Health

Aleksandra Rizo Appointed as CEO of Vividion Therapeutics

January 25, 2023

OPPO Pledges Carbon Neutrality Across its Operations by 2050 at MWC 2023

March 2, 2023

...

GE Renewable Energy continues to add wind power to Lithuania

March 3, 2023

...

Interview with Mr. Sébastien Huron, CEO, Virbac group

March 6, 2023

...

European Corporate Development & Strategy Awards

March 9, 2023

...

L’ORÉAL INVESTS IN BIOTECHNOLOGY VENTURE TO SCALE DEVELOPMENT OF PLANT-BASED INGREDIENTS FOR SUSTAINABLE BEAUTY

March 22, 2023

...

Infineon and UMC extend automotive partnership with long-term agreement for 40nm eNVM microcontroller production

March 8, 2023

...

Schneider Electric investing €40 million in new smart factory in Hungary

March 23, 2023

...

Yvonne Bettkober to be Head of Organizational Development and Transformation for the Volkswagen Group

March 7, 2023

...

Efficient and high-performing vehicle architecture: Cooperation of Continental and Infineon

March 14, 2023

...

default

Voith Hydro opens new center of competence for generator components

March 8, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist